We’re redefining early disease detection with cutting-edge diagnostic programs targeting rare, cardiac, and neurodegenerative conditions.
All tests are minimally invasive and blood-based, delivering high accuracy rates in early clinical data.
As a spinout from UCL, we maintain a continuous pipeline of breakthrough science, helping partners accelerate clinical development and transform patient outcomes worldwide.
-
PARKINSON'S DISEASE
- No clinically available rapid-turnaround diagnostic test for PD
- Current diagnosis relies on clinical investigation, costly imaging (DATscan), and invasive CSF testing (SYNTap)
- 200,000 new PD cases annually in USA, UK, and EU; expected to double by 2050
-
HYPERTROPHIC CARDIOMYOPATHY (HCM)
- Most common genetic cardiac disease
- Leading cause of sudden cardiac death in children
- Massively underdiagnosed
- Diagnosis relies on imaging, not viable for wider population
-
IMMUNOGENICITY
- Immunogenicity remains one of the most critical challenges in modern therapeutics, influencing safety, efficacy, and long-term outcomes across gene therapies and biologics.
- Despite its importance, tools for accurately measuring and interpreting immune responses across the treatment journey remain semi-quantitative and lack conformity.
- ImmunoTADA addresses this gap by enabling precise, scalable profiling of immune responses—supporting better decision-making from development through clinical care.
OUR DIAGNOSTIC SOLUTIONS
PD Predict™
A blood-based, targeted proteomic biomarker panel for Parkinson's disease.
- Identifies Parkinson’s patients with 100% accuracy in initial studies
- Predicts disease development up to 7 years before symptoms appear
- Backed by FDA Breakthrough Device Designation, setting a new standard in early detection
HCM Predict™
Leading the way with the world’s first blood-based biomarker panel for HCM.
- Achieves high accuracy in identifying patients with Hypertrophic Cardiomyopathy
- Partnering with leading pharma to validate and launch this first-of-its-kind test
- Recognised with FDA Breakthrough Device Designation, setting a new benchmark in cardiac diagnostics
ImmunoTADA™
The future of immunogenicity testing, built for protein therapeutics and gene therapy vectors.
- Next generation testing platform for quantifying a patient’s complete immunocomplex response
- A game-changer for gene therapy, currently in head-to-head studies to establish the new global gold standard
- Designed to transform immune monitoring and accelerate advanced therapeutic development
PIPELINE OF NEW DIAGNOSTICS
WITH CLEAR UK MARKET ACCESS
EXPLORE OUR RANGE OF DIAGNOSTICS
Let’s talk precision.
Schedule a meeting with our team now.
Book a Meeting with Our Experts >
